BET Protein Inhibition for Pulmonary Arterial Hypertension

Mar 14, 2022

1 min read

Updated: Nov 7, 2024

This pilot study added apabetalone to people's PAH therapy twice daily for 16 weeks to see if a future clinical trial evaluating bromodomain inhibition in pulmonary arterial hypertension might be feasible. They also aimed to provide preliminary evidence that apabetalone may be safe and effective in PAH.

Read the original journal article

Recent Posts

Patient and Clinician Views on Shared Decision-Making

Preference for shared decision-making was nearly universal among patients and clinicians. However, priorities differed significantly. Patients more frequently emphasized quality of life (81% vs. 54%)

Why lived experience must shape research

"Drawing on decades of patient advocacy, two women living with the rare condition Congenital Melanocytic Naevus argue that lived experience must shape research from the outset, and discuss how genuine

More than half of pulmonary fibrosis patients have PH

There is not much data looking at pulmonary hypertension (PH) in interstitial lung disease, except in idiopathic pulmonary fibrosis (IPF). A study of patients with pulmonary fibrosis found that 60.7%

Comments